




Author index

Volume 299 (2000)

- Abbritti, G., see Tassi, C. 299, 55
Adachi, M., see Hirano, T. 299, 65
Ahmed, S., see Mantle, D. 299, 1
Alberti, L., see Seghieri, G. 299, 109
Alling, C., see Varga, A. 299, 141
Amant, C., see Boullier, A. 299, 129
Amino, N., see Fujita, A. 299, 179
Amouyel, P., see Boullier, A. 299, 129
Anichini, R., see Seghieri, G. 299, 109
Araake, H., see Sugawara, K. 299, 45
Assmann, G., see Lorkowski, S. 299, 199
Avilov, V.V., see Nikulina, V.A. 299, 25
- Bernardi, D., see Plebani, M. 299, 77
Bertrand, M., see Boullier, A. 299, 129
Boullier, A., Walters-Laporte, E., Hamon, M., Tailleux, A., Amant, C., Amouyel, P., Fruchart, J.-C., Bertrand, M., Duriez, P., Absence of relationship between plasma Lp(a), Lp-AI, anti-oxidized LDL autoantibodies, LDL immune complexes concentrations and restenosis after percutaneous transluminal coronary angioplasty 299, 129
Busis, S.N., see Kelly, R.H. 299, 205
Bustos, P., Ulloa, N., Calvo, C., Muller, D., Durán, D., Martínez, J., Salazar, L., Quiroga, A., Monoclonal antibodies to human apolipoproteins: application to the study of high density lipoprotein subpopulations 299, 151
- Calvo, C., see Bustos, P. 299, 151
Cullen, P., see Lorkowski, S. 299, 199
- De Giorgio, L.A., see Seghieri, G. 299, 109
Di Simplicio, P., see Seghieri, G. 299, 109
Dmitriev, A.D., see Nikulina, V.A. 299, 25
Durán, D., see Bustos, P. 299, 151
- Duriez, P., see Boullier, A. 299, 129
- Ellinghaus, P., see Lorkowski, S. 299, 199
- Feligioni, L., see Tassi, C. 299, 55
Franconi, F., see Seghieri, G. 299, 109
Fruchart, J.-C., see Boullier, A. 299, 129
Fujio, S., see Shimasaki, A.K. 299, 119
Fujita, A., Kuroda, S., Tada, H., Hidaka, Y., Kimura, M., Takeoka, K., Nagata, S., Sato, H., Amino, N., Enzyme-linked immunosorbent assay for anti-tropomyosin antibodies and its clinical application to various heart diseases 299, 179
Fujita, K., see Shimasaki, A.K. 299, 119
Fujitaka, M., Nomura, S., Sakura, N., Ueda, K., Matuura, R., Yumiba, C., Morning and afternoon serum levels of cortisone and cortisol in asthmatic patients 299, 101
Funato, T., see Miura, T. 299, 87
Furuya, D., see Sugawara, K. 299, 45
- Galinski, E.A., see Lorkowski, S. 299, 199
Gomi, K., see Kimura, S. 299, 169
Guillot, M., see Monier, F. 299, 11
- Hamon, M., see Boullier, A. 299, 129
Hansson, P., see Varga, A. 299, 141
Hidaka, Y., see Fujita, A. 299, 179
Hirabayashi, T., see Mitsui, T. 299, 193
Hirano, T., Ookubo, K., Kashiwazaki, K., Tajima, H., Yoshino, G., Adachi, M., Vascular endothelial markers, von willebrand factor and thrombomodulin index, are specifically elevated in type 2 diabetic patients with nephropathy: comparison of primary renal disease 299, 65
Hosoda, K., see Sugawara, K. 299, 45

- Johnson, G., see Varga, A. 299, 141
- Kaizu, T., see Kimura, S. 299, 169
- Kaku, M., see Miura, T. 299, 87
- Kamimura, T., see Sugawara, K. 299, 45
- Kashiwazaki, K., see Hirano, T. 299, 65
- Kelly, C.M., see Kelly, R.H. 299, 205
- Kelly, R.H., Kelly, C.M., Busis, S.N., Factitious hearing loss and otorrhea in an adolescent boy 299, 205
- Kim, D., see Kimura, S. 299, 169
- Kimura, M., see Fujita, A. 299, 179
- Kimura, S., Numaguchi, M., Kaizu, T., Kim, D., Takagi, Y., Gomi, K., High galactosylation of oligosaccharides in umbilical cord blood IgG, and its relationship to placental function 299, 169
- Kizim, E.A., see Nikulina, V.A. 299, 25
- Kobayashi, D., see Sugawara, K. 299, 45
- Kolyaskina, G.I., see Nikulina, V.A. 299, 25
- Kondo, T., see Mitsui, T. 299, 193
- Kuroda, S., see Fujita, A. 299, 179
- Lorkowski, S., Ellinghaus, P., Galinski, E.A., Asmann, G., Cullen, P., Use of longer extension phases to improve yield of high molecular weight products in differential display PCR 299, 199
- MacNee, W., see Mantle, D. 299, 1
- Mancuso, F., see Tassi, C. 299, 55
- Mantle, D., Patel, V.B., Why, H.J.F., Ahmed, S., Rahman, I., MacNee, W., Wassif, W.S., Richardson, P.J., Preedy, V.R., Effects of lisinopril and amlodipine on antioxidant status in experimental hypertension 299, 1
- Martínez, J., see Bustos, P. 299, 151
- Massino, Y.S., see Nikulina, V.A. 299, 25
- Matuura, R., see Fujitaka, M. 299, 101
- Meneghetti, M.F., see Plebani, M. 299, 77
- Mitsui, T., Naitoh, K., Tsuda, T., Hirabayashi, T., Kondo, T., Is endogenous isoprene the only coeluting compound in the measurement of breath pentane? 299, 193
- Miura, T., Funato, T., Yabuki, S., Sasaki, T., Kaku, M., Detection of monoclonal proteins by capillary electrophoresis using a zwitterion in the running buffer 299, 87
- Monier, F., Surla, A., Guillot, M., Morel, F., Gelatinase isoforms in urine from bladder cancer patients 299, 11
- Morel, F., see Monier, F. 299, 11
- Morucci, P., see Tassi, C. 299, 55
- Muller, D., see Bustos, P. 299, 151
- Muzi, G., see Tassi, C. 299, 55
- Nagata, S., see Fujita, A. 299, 179
- Naitoh, K., see Mitsui, T. 299, 193
- Nikulina, V.A., Kizim, E.A., Massino, Y.S., Segal, O.L., Smirnova, M.B., Avilov, V.V., Saprigin, D.B., Smotrov, S.P., Tichtchenko, V.A., Kolyaskina, G.I., Dmitriev, A.D., Synergistic effects in antigen capture ELISA using three monoclonal antibodies directed at different epitopes of the same antigen 299, 25
- Nomura, S., see Fujitaka, M. 299, 101
- Numaguchi, M., see Kimura, S. 299, 169
- Ookubo, K., see Hirano, T. 299, 65
- Patel, V.B., see Mantle, D. 299, 1
- Plebani, M., Bernardi, D., Meneghetti, M.F., Ujka, F., Zaninotto, M., Biological variability in assessing the clinical value of biochemical markers of bone turnover 299, 77
- Preedy, V.R., see Mantle, D. 299, 1
- Quiroga, A., see Bustos, P. 299, 151
- Rahman, I., see Mantle, D. 299, 1
- Richardson, P.J., see Mantle, D. 299, 1
- Saito, K., see Sugawara, K. 299, 45
- Sakura, N., see Fujitaka, M. 299, 101
- Sakurabayashi, I., see Shimasaki, A.K. 299, 119
- Salazar, L., see Bustos, P. 299, 151
- Saprigin, D.B., see Nikulina, V.A. 299, 25
- Sasaki, T., see Miura, T. 299, 87
- Sato, H., see Fujita, A. 299, 179
- Segal, O.L., see Nikulina, V.A. 299, 25
- Seghieri, G., Di Simplicio, P., De Giorgio, L.A., Anichini, R., Alberti, L., Franconi, F., Relationship between metabolic glycaemic control and platelet content of glutathione and its related enzymes, in insulin-dependent diabetes mellitus 299, 109
- Shimasaki, A.K., Fujita, K., Fujio, S., Sakurabayashi, I., Pseudoleukocytosis without pseudothrombocytopenia induced by the interaction of EDTA and IgG₂-κ M-protein 299, 119
- Smirnova, M.B., see Nikulina, V.A. 299, 25
- Smotrov, S.P., see Nikulina, V.A. 299, 25
- Sugawara, K., Kobayashi, D., Saito, K., Furuya, D., Araake, H., Yagihashi, A., Yajima, T., Hosoda, K., Kamimura, T., Watanabe, N., A highly sensitive immuno-polymerase chain reaction assay for human angiotensinogen using the identical first and second polyclonal antibodies 299, 45
- Surla, A., see Monier, F. 299, 11

- Tada, H., see Fujita, A. 299, 179
- Tailleux, A., see Boullier, A. 299, 129
- Tajima, H., see Hirano, T. 299, 65
- Takagi, Y., see Kimura, S. 299, 169
- Takeoka, K., see Fujita, A. 299, 179
- Tassi, C., Abbritti, G., Mancuso, F., Morucci, P., Feligioni, L., Muzi, G., Activity and isoenzyme profile of *N*-acetyl- β -D-glucosaminidase in urine from workers exposed to cadmium 299, 55
- Tichtchenko, V.A., see Nikulina, V.A. 299, 25
- Tsuda, T., see Mitsui, T. 299, 193
- Ueda, K., see Fujitaka, M. 299, 101
- Ujka, F., see Plebani, M. 299, 77
- Ulloa, N., see Bustos, P. 299, 151
- Varga, A., Hansson, P., Johnson, G., Alling, C., Normalization rate and cellular localization of phosphatidylethanol in whole blood from chronic alcoholics 299, 141
- Walters-Laporte, E., see Boullier, A. 299, 129
- Wassif, W.S., see Mantle, D. 299, 1
- Watanabe, N., see Sugawara, K. 299, 45
- Why, H.J.F., see Mantle, D. 299, 1
- Yabuki, S., see Miura, T. 299, 87
- Yagihashi, A., see Sugawara, K. 299, 45
- Yajima, T., see Sugawara, K. 299, 45
- Yoshino, G., see Hirano, T. 299, 65
- Yumiba, C., see Fujitaka, M. 299, 101
- Zaninotto, M., see Plebani, M. 299, 77



Subject index

Volume 299 (2000)

-
- N*-Acetyl- β -D-glucosaminidase**; Cadmium; Urine; Isoenzyme **299**, 55
- Ambient air**; Breath; Pentane; Isopentane; Isoprene **299**, 193
- Amlodipine**; Free radicals; Antioxidants; Hypertension; Lisinopril **299**, 1
- Angioplasty**; LDL; HDL; Lp(a); LpAI; Antioxidized-LDL autoantibodies; LDL immune complexes; Stenosis **299**, 129
- Angiotensinogen**; Enzyme-linked immunosorbent assay; Polymerase chain reaction **299**, 45
- Annealing temperature**; Differential display PCR; Extension time **299**, 199
- Anti-heart antibody**; Anti-tropomyosin antibody, Anti-myosin antibody, Heart disease **299**, 179
- Anti-tropomyosin antibody, Anti-myosin antibody, Heart disease**; Anti-heart antibody **299**, 179
- Antigen capture ELISA**; Three-site; Monoclonal antibodies; Synergistic effect; Human myoglobin **299**, 25
- Antioxidants**; Free radicals; Hypertension; Lisinopril; Amlodipine **299**, 1
- Antioxidized-LDL autoantibodies**; LDL; HDL; Lp(a); LpAI; LDL immune complexes; Angioplasty; Stenosis **299**, 129
- Asthma**; Cortisol; Cortisone; Diurnal change **299**, 101
- Biological variability**; Urinary bone markers; Critical differences; Index of individuality **299**, 77
- Bladder cancer**; Gelatinase; Neutrophil gelatinase-Associated lipocalin (NGAL); Preparative electrophoresis **299**, 11
- Blood**; Phosphatidylethanol; Compartment; Normalization; Half-life; Chronic alcoholics **299**, 141
- Breath**; Ambient air; Pentane; Isopentane; Isoprene **299**, 193
- Cadmium**; Urine; *N*-Acetyl- β -D-glucosaminidase; Isoenzyme **299**, 55
- Capillary zone electrophoresis**; Monoclonal protein; Zwitterion **299**, 87
- Carbohydrate**; Cord blood; IgG; Galactosylation; Placental function **299**, 169
- Chronic alcoholics**; Phosphatidylethanol; Compartment; Normalization; Half-life; Blood **299**, 141
- Compartment**; Phosphatidylethanol; Normalization; Half-life; Blood; Chronic alcoholics **299**, 141
- Cord blood**; IgG; Carbohydrate; Galactosylation; Placental function **299**, 169

- Cortisol**; Asthma; Cortisone; Diurnal change **299**, 101
- Cortisone**; Asthma; Cortisol; Diurnal change **299**, 101
- Critical differences**; Biological variability; Urinary bone markers; Index of individuality **299**, 77
- Diabetic microangiopathy**; Insulin-dependent diabetes mellitus; Metabolic control; Platelet glutathione; Glutathione related enzymes **299**, 109
- Diabetic nephropathy**; Vascular endothelial damage; Primary renal disease; Von Willebrand factor; Thrombomodulin index **299**, 65
- Differential display PCR**; Extension time; Annealing temperature **299**, 199
- Diurnal change**; Asthma; Cortisol; Cortisone **299**, 101
- EDTA**; IgG₂; M-protein; Pseudoleukocytosis **299**, 119
- Enzyme-linked immunosorbent assay**; Angiotensinogen; Polymerase chain reaction **299**, 45
- Extension time**; Differential display PCR; Annealing temperature **299**, 199
- Free radicals**; Antioxidants; Hypertension; Lisinopril; Amlodipine **299**, 1
- Galactosylation**; Cord blood; IgG; Carbohydrate; Placental function **299**, 169
- Gelatinase**; Neutrophil gelatinase-Associated lipocalin (NGAL); Bladder cancer; Preparative electrophoresis **299**, 11
- Glutathione related enzymes**; Insulin-dependent diabetes mellitus; Metabolic control; Platelet glutathione; Diabetic microangiopathy **299**, 109
- HDL**; LDL; Lp(a); LpAI; Antioxidized-LDL autoantibodies; LDL immune complexes; Angioplasty; Stenosis **299**, 129
- Half-life**; Phosphatidylethanol; Compartment; Normalization; Blood; Chronic alcoholics **299**, 141
- High density lipoproteins**; Monoclonal antibodies; Lipoparticles LpA-I; Lipoparticles LpA-I:A-II; Quantification **299**, 151
- Human myoglobin**; Antigen capture ELISA; Three-site; Monoclonal antibodies; Synergistic effect **299**, 25
- Hypertension**; Free radicals; Antioxidants; Lisinopril; Amlodipine **299**, 1
- IgG**; Cord blood; Carbohydrate; Galactosylation; Placental function **299**, 169
- IgG₂**; M-protein; EDTA; Pseudoleukocytosis **299**, 119
- Index of individuality**; Biological variability; Urinary bone markers; Critical differences **299**, 77
- Insulin-dependent diabetes mellitus**; Metabolic control; Platelet glutathione; Glutathione related enzymes; Diabetic microangiopathy **299**, 109
- Isoenzyme**; Cadmium; Urine; *N*-Acetyl- β -D-glucosaminidase **299**, 55
- Isopentane**; Breath; Ambient air; Pentane; Isoprene **299**, 193
- Isoprene**; Breath; Ambient air; Pentane; Isopentane **299**, 193
- LDL immune complexes**; LDL; HDL; Lp(a); LpAI; Antioxidized-LDL autoantibodies; Angioplasty; Stenosis **299**, 129
- LDL**; HDL; Lp(a); LpAI; Antioxidized-LDL autoantibodies; LDL immune complexes; Angioplasty; Stenosis **299**, 129
- Lipoparticles LpA-I:A-II**; High density lipoproteins; Monoclonal antibodies; Lipoparticles LpA-I; Quantification **299**, 151
- Lipoparticles LpA-I**; High density lipoproteins; Monoclonal antibodies; Lipoparticles LpA-I:A-II; Quantification **299**, 151
- Lisinopril**; Free radicals; Antioxidants; Hypertension; Amlodipine **299**, 1
- Lp(a)**; LDL; HDL; LpAI; Antioxidized-LDL autoantibodies; LDL immune complexes; Angioplasty; Stenosis **299**, 129

- LpAI**; LDL; HDL; Lp(a); Antioxidized-LDL autoantibodies; LDL immune complexes; Angioplasty; Stenosis 299, 129
- M-protein**; IgG₂; EDTA; Pseudoleukocytosis 299, 119
- Metabolic control**; Insulin-dependent diabetes mellitus; Platelet glutathione; Glutathione related enzymes; Diabetic microangiopathy 299, 109
- Monoclonal antibodies**; Antigen capture ELISA; Three-site; Synergistic effect; Human myoglobin 299, 25
- Monoclonal antibodies**; High density lipoproteins; Lipoparticles LpA-I; Lipoparticles LpA-I:A-II; Quantification 299, 151
- Monoclonal protein**; Capillary zone electrophoresis; Zwitterion 299, 87
- Neutrophil gelatinase-Associated lipocalin (NGAL)**; Gelatinase; Bladder cancer; Preparative electrophoresis 299, 11
- Normalization**; Phosphatidylethanol; Compartment; Half-life; Blood; Chronic alcoholics 299, 141
- Pentane**; Breath; Ambient air; Isopentane; Isoprene 299, 193
- Phosphatidylethanol**; Compartment; Normalization; Half-life; Blood; Chronic alcoholics 299, 141
- Placental function**; Cord blood; IgG; Carbohydrate; Galactosylation 299, 169
- Platelet glutathione**; Insulin-dependent diabetes mellitus; Metabolic control; Glutathione related enzymes; Diabetic microangiopathy 299, 109
- Polymerase chain reaction**; Angiotensinogen; Enzyme-linked immunosorbent assay 299, 45
- Preparative electrophoresis**; Gelatinase; Neutrophil gelatinase-Associated lipocalin (NGAL); Bladder cancer 299, 11
- Primary renal disease**; Vascular endothelial damage; Diabetic nephropathy; Von Willebrand factor; Thrombomodulin index 299, 65
- Pseudoleukocytosis**; IgG₂; M-protein; EDTA 299, 119
- Quantification**; High density lipoproteins; Monoclonal antibodies; Lipoparticles LpA-I; Lipoparticles LpA-I:A-II 299, 151
- Salivary transferrin**; Transferrin isoforms; β_2 Transferrin 299, 205
- Stenosis**; LDL; HDL; Lp(a); LpAI; Antioxidized-LDL autoantibodies; LDL immune complexes; Angioplasty 299, 129
- Synergistic effect**; Antigen capture ELISA; Three-site; Monoclonal antibodies; Human myoglobin 299, 25
- Three-site**; Antigen capture ELISA; Monoclonal antibodies; Synergistic effect; Human myoglobin 299, 25
- Thrombomodulin index**; Vascular endothelial damage; Diabetic nephropathy; Primary renal disease; Von Willebrand factor 299, 65
- β_2 Transferrin**; Transferrin isoforms; Salivary transferrin 299, 205
- Transferrin isoforms**; β_2 Transferrin; Salivary transferrin 299, 205
- Urinary bone markers**; Biological variability; Critical differences; Index of individuality 299, 77
- Urine**; Cadmium; *N*-Acetyl- β -D-glucosaminidase; Isoenzyme 299, 55
- Vascular endothelial damage**; Diabetic nephropathy; Primary renal disease; Von Willebrand factor; Thrombomodulin index 299, 65
- Von Willebrand factor**; Vascular endothelial damage; Diabetic nephropathy; Primary renal disease; Thrombomodulin index 299, 65
- Zwitterion**; Capillary zone electrophoresis; Monoclonal protein 299, 87

